Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IKQCL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
H2-921
|
|||||
| Synonyms |
Trastuzume -VA-SB743921
Click to Show/Hide
|
|||||
| Organization |
Academy of Military Medicine, PLA Academy of Military Sciences
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.66
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
SB743921
|
Payload Info | ||||
| Therapeutic Target |
Kinesin spindle protein (KSP)
|
Target Info | ||||
| Linker Name |
CN118987256A, H2-921, Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Linker+SB743921 (D7)
|
|||||
ADC-specific functional property(2027 Update)
Circulating Stability
| Incubation Time | 7day | Release | <10ng/mL | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | H2-921 was dissolved in human plasma (initial concentration of H2-921 was 400ug/ml in human plasma), and incubated at 37 °C for 7 days. Samples were taken at the predetermined time (0.0833, 0.5, 1, 4, 8, 12, 24, 48, 96, 168h) and the content of free SB743921 in plasma was determined by LC-MS/MS method. | ||||
| Description |
H2-921 can significantly prolong SB743921 in serum of different species Half-life period.
|
||||
| Incubation Time | 7day | Release | <10ng/mL | Reference |
[1]
|
| Incubation Medium | H2-921 was dissolved in monkey plasma (initial concentration of H2-921 was 400ug/ml in monkey plasma), and incubated at 37 °C for 7 days. Samples were taken at the predetermined time (0.0833, 0.5, 1, 4, 8, 12, 24, 48, 96, 168h) and the content of free SB743921 in plasma was determined by LC-MS/MS method. | ||||
| Description |
H2-921 can significantly prolong SB743921 in serum of different species Half-life period.
|
||||
| Incubation Time | 8hr | Release | ≈80ng/mL | Reference |
[1]
|
| Incubation Medium | H2-921 was dissolved in lysosomal system (0.02 mg/ml of lysosomal PBS buffer), initial concentration of H2-921 was 20ug/ml in lysosomal system, and incubated at 37 °C for 7 days. Samples were taken at the predetermined time (0.0833, 0.5, 1, 4, 8, 12, 24, 48, 96, 168h) and the content of free SB743921 in plasma was determined by LC-MS/MS method. | ||||
| Description |
H2-921 can significantly prolong SB743921 in serum of different species Half-life period.
|
||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 73.30% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Female nude mice (5 ~ 6 weeks old, weight about 20g) were included in the experiment after 1 week of adaptive feeding. It's going to be about 5 x 10Six SKOV-3 cells were inoculated under the skin of the right hind limb of mice to observe the tumor formation. When the tumor volume reached 120mm3, the mice were randomly divided into treatment group and control group (n = 6 groups). H2-921 at 0.5 mg/kg, T-DM1 (1.5 mg/kg, positive control) and PBS (control) were administered at day 0, 7 and 14, respectively. Animal weight was monitored every 3 days and animal behavior was observed daily.Tumor volume was monitored every 3 days during treatment and calculated using the formula TV = a× B2/3, where a represents the long diameter of each tumor and b represents the short diameter of each tumor.
Click to Show/Hide
|
||||
| In Vivo Model | SKOV3 tumor bearing female nude mouse model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 83.30% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Female nude mice (5 ~ 6 weeks old, weight about 20g) were included in the experiment after 1 week of adaptive feeding. It's going to be about 5 x 10Six SKOV-3 cells were inoculated under the skin of the right hind limb of mice to observe the tumor formation. When the tumor volume reached 120mm3, the mice were randomly divided into treatment group and control group (n = 6 groups). H2-921 at 1.5 mg/kg, T-DM1 (1.5 mg/kg, positive control) and PBS (control) were administered at day 0, 7 and 14, respectively. Animal weight was monitored every 3 days and animal behavior was observed daily.Tumor volume was monitored every 3 days during treatment and calculated using the formula TV = a× B2/3, where a represents the long diameter of each tumor and b represents the short diameter of each tumor.
Click to Show/Hide
|
||||
| In Vivo Model | SKOV3 tumor bearing female nude mouse model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 99.60% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Female nude mice (5 ~ 6 weeks old, weight about 20g) were included in the experiment after 1 week of adaptive feeding. It's going to be about 5 x 10Six SKOV-3 cells were inoculated under the skin of the right hind limb of mice to observe the tumor formation. When the tumor volume reached 120mm3, the mice were randomly divided into treatment group and control group (n = 6 groups). H2-921 at 4.5 mg/kg, T-DM1 (1.5 mg/kg, positive control) and PBS (control) were administered at day 0, 7 and 14, respectively. Animal weight was monitored every 3 days and animal behavior was observed daily.Tumor volume was monitored every 3 days during treatment and calculated using the formula TV = a× B2/3, where a represents the long diameter of each tumor and b represents the short diameter of each tumor.
Click to Show/Hide
|
||||
| In Vivo Model | SKOV3 tumor bearing female nude mouse model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | . log10 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
BT-474 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | . log10 ng/mL | Negative HER2 expression (HER2-) | ||
| Method Description |
IOSE80 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Normal | IOSE80 cells | CVCL_5546 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | . log10 ng/mL | Negative HER2 expression (HER2-) | ||
| Method Description |
GES-1 cells were inoculated in 96-well plates with 5×103 cells/Wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Normal | GES-1 cells | CVCL_EQ22 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | . log10 ng/mL | Negative HER2 expression (HER2-) | ||
| Method Description |
MDA-MB-468 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.8 log10 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SKOV-3 cells were inoculated in 96-well plates at 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3.5 log10 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SK-BR-3 cells were inoculated in 96-well plates with 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 5 log10 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
NCI-N87 were inoculated in 96-well plates at 5×103 cells/wells and cultured overnight at 37°C with 5% CO2. Then trastuzumab, SB743921, linker+SB743921 or H were added at concentrations of 100ug/ml, 10ug/ml, 1ug/ml, 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 1pg/ml or 0mg/ml, respectively 2-921. After culture at 37°C and 5% CO2 for 48h, 10ul CCK-8 solution was added to each well. After 2 ~ 4h, the absorbance at 450nm was measured by enzymograph, and the cell survival rate was calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | apoptosis | 24.05% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SKOV-3 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 1 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | apoptosis | 38.19% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
NCI-N87 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 1 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | apoptosis | 51.63% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
NCI-N87 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 10 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | apoptosis | 58.87% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
NCI-N87 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 100 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | apoptosis | 78.59% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SKOV-3 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 10 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | apoptosis | 82.56% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SKOV-3 cells were inoculated in 6-well plates at about 1×106 cells per well and incubated overnight at 37°C with 5% CO2. The cells were then treated with 100 ug/ml H2-921 for 48 hours. The cells were then collected, suspended with pre-cooled 70% alcohol and fixed overnight at 4 °C. The cells were then incubated with RNase A at 37 °C, RNase A was removed again, and the cells were suspended with propyl iodide (PI) staining solution. 30min dull staining and FACSCalibur flow cytometry. For apoptosis analysis, the cells were treated as described above, and apoptosis was detected by Annexin V-FITC/PI double staining apoptosis kit (Dojindo, Japan) after 48h. Cell cycle distribution and apoptosis were detected by FACSCalibur flow cytometry.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||
